CLRB
Income statement / Annual
Last year (2025), Cellectar Biosciences Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Cellectar Biosciences Inc's net income was -$21.79 M.
See Cellectar Biosciences Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$213.60 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$189.36 K
|
$82.27 K
|
$1.55 M
|
$356.67 K
|
| Gross Profit |
-$213.60 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$189.36 K
|
-$82.27 K
|
-$1.55 M
|
-$356.67 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$11.50 M
|
$26.14 M
|
$27.27 M
|
$19.22 M
|
$17.59 M
|
$10.14 M
|
$9.00 M
|
$6.84 M
|
$9.47 M
|
$4.75 M
|
| General & Administrative Expenses |
$11.48 M
|
$25.64 M
|
$11.69 M
|
$9.59 M
|
$6.54 M
|
$5.15 M
|
$0.00
|
$4.82 M
|
$4.14 M
|
$4.70 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.48 M
|
$25.64 M
|
$11.69 M
|
$9.59 M
|
$6.54 M
|
$5.15 M
|
$4.99 M
|
$4.82 M
|
$4.14 M
|
$4.70 M
|
| Other Expenses |
-$213.60 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$22.77 M
|
$51.78 M
|
$38.96 M
|
$28.81 M
|
$24.13 M
|
$15.29 M
|
$13.99 M
|
$11.66 M
|
$13.60 M
|
$9.45 M
|
| Cost And Expenses |
$22.98 M
|
$51.78 M
|
$38.96 M
|
$28.81 M
|
$24.13 M
|
$15.29 M
|
$14.18 M
|
$11.66 M
|
$13.60 M
|
$9.45 M
|
| Interest Income |
$435.10 K
|
$1.21 M
|
$387.15 K
|
$152.52 K
|
$2.28 K
|
$10.90 K
|
$42.71 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$29.69 K
|
$16.61 K
|
$7.90 K
|
| Depreciation & Amortization |
$213.60 K
|
$291.65 K
|
$192.38 K
|
$148.44 K
|
$149.92 K
|
$207.93 K
|
$189.36 K
|
$82.27 K
|
$1.55 M
|
$356.67 K
|
| EBITDA |
-$22.77 M |
-$51.49 M |
-$38.77 M |
-$28.67 M |
-$23.98 M |
-$14.89 M |
-$13.90 M |
-$13.16 M |
-$12.05 M |
-$9.09 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.19 M
|
$7.26 M
|
-$3.87 M
|
-$3.04 M
|
$8.92 K
|
$196.18 K
|
$85.71 K
|
-$1.58 M
|
$38.68 K
|
$3.27 M
|
| Income Before Tax |
-$21.79 M
|
-$44.52 M
|
-$42.83 M
|
-$31.85 M
|
-$24.12 M
|
-$15.09 M
|
-$14.09 M
|
-$13.24 M
|
-$13.56 M
|
-$6.18 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$66.00 K
|
-$60.00 K
|
-$60.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$21.79 M
|
-$44.58 M
|
-$42.77 M
|
-$31.79 M
|
-$24.12 M
|
-$15.09 M
|
-$14.09 M
|
-$13.24 M
|
-$13.56 M
|
-$6.18 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-8.35 |
-36.5196 |
-104.988 |
-135.1791 |
-130.353 |
-228.552 |
-550.857 |
-1567.959 |
-3210 |
-6420 |
| EPS Diluted |
-8.35 |
-41.8902 |
-104.988 |
-135.1791 |
-130.353 |
-228.552 |
-550.857 |
-1567.959 |
-3210 |
-6420 |
| Weighted Average Shares Out |
$2.61 M
|
$1.22 M
|
$407.39 K
|
$235.19 K
|
$185.05 K
|
$66.04 K
|
$25.58 K
|
$9.87 K
|
$4.68 K
|
$1.46 K
|
| Weighted Average Shares Out Diluted |
$2.61 M
|
$1.24 M
|
$407.39 K
|
$235.19 K
|
$185.05 K
|
$66.04 K
|
$25.58 K
|
$9.87 K
|
$4.68 K
|
$1.46 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
